Sialic acid as a potential biomarker for cardiovascular disease, diabetes and cancer
| Autor: | Helen Mi Osborn, Daniel Ir Spencer, Jack Cheeseman, Gunter G. C. Kuhnle, Richard A. Gardner, Graham P. Stafford |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty Clinical Biochemistry Disease Pathogenesis 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Diabetes mellitus Internal medicine Drug Discovery Medicine Effective treatment business.industry Biochemistry (medical) Disease progression Cancer medicine.disease Sialic acid 030104 developmental biology chemistry Cardiovascular Diseases 030220 oncology & carcinogenesis Potential biomarkers business |
| Zdroj: | Biomarkers in medicine. 15(11) |
| ISSN: | 1752-0371 1752-0363 |
| Popis: | Cardiovascular disease (CVD), diabetes and cancer pose increasing global healthcare burdens. New biomarkers could enable earlier diagnosis of these diseases, leading to more effective treatment and lower associated healthcare burden. Elevated sialic acid concentration in plasma and serum has been positively correlated with the presence of CVDs, diabetes and the development of malignant tumors. This article reviews the use of total sialic acid (TSA), bound sialic acid (BSA) and free sialic acid (FSA) as potential biomarkers for these diseases and makes a comparison with existing markers. Elevated sialic acid has been shown to be indicative of the pathogenesis of CVD, diabetes and malignant tumors. While not a specific marker for one disease there is promise in utilizing sialic acid as a marker for monitoring disease progression and effectiveness of treatment programs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|